Investigating HPV Vaccination Uptake in Adults Aged 18-35 Seeking Care at a Health Clinic in Rural Mississippi

Sponsor
Plan A Health, Inc (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05658198
Collaborator
Merck Sharp & Dohme LLC (Industry)
100
1
8.8
11.3

Study Details

Study Description

Brief Summary

A study evaluating HPV vaccine uptake among unvaccinated patients between the ages of 18 and 35 of a mobile health clinic serving the Mississippi Delta.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Counseling

Detailed Description

This study is intended to serve several purposes. The first is to determine whether patients between the ages of 18 and 35 visiting a mobile health clinic or brick and mortar clinic in the Mississippi Delta who have not received the HPV vaccine or have not completed the vaccine series are receptive to receiving it while seeking care. The second purpose is to determine whether those patients who initially decline the HPV vaccine are interested in receiving it after being counseled about HPV and the potential effects of the virus. The third purpose is to assess whether there is a statistically significant difference between the type of visit people who opt to receive the vaccine are making to the clinics. Finally, the knowledge, attitudes, and perceptions around HPV and the HPV vaccine will be assessed via group interviews with eligible participants at the conclusion of the study.

The study also includes two secondary objectives. The first is to assess whether adults who are not vaccinated against HPV are interested in receiving it. The second is to assess whether adults accurately recall whether they received a specific vaccine during childhood. The implications from these two objectives have the potential to influence policy changes regarding vaccine catch-up among adults and health communication practices as young adults transition out of pediatric care.

Anyone between the ages of 18 and 35 whose vaccination status can be verified is eligible to be enrolled in this study.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Non-controlled Trial to Determine Whether Counseling Around HPV Increases Vaccine Uptake in Unvaccinated Patients Ages 18-35 Visiting a Rural Health Clinic for Primary or Reproductive Health-related Care in the Mississippi Delta
Actual Study Start Date :
Dec 6, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Unvaccinated patients

Patients who are unvaccinated against HPV when they arrive at Plan A.

Behavioral: Counseling
Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.

Outcome Measures

Primary Outcome Measures

  1. Increased HPV vaccination rates [one year]

    Determine whether offering the HPV vaccine free of charge to unvaccinated adults aged 18-35 receiving SRH or primary care services at a primarily mobile health clinic serving mainly low-income patients of color changes vaccination rates in the community.

  2. Counseling effectiveness [one year]

    Determine whether a 3-5 minute education session on HPV and HPV-related diseases for people who decline initial vaccination changes their vaccination intentions.

  3. Visit differences [one year]

    Determine whether a significant difference exists between the type of visit (SRH versus primary care) patients who decide to become vaccinated made to the clinic.

  4. Prior information [one year]

    Examine how access to and prior information given on the HPV vaccine, as well as risk assessment for HPV infection versus vaccination, among unvaccinated adults between 18 and 35, addresses vaccine discordancy and affects the decision to become vaccinated as an adult.

Secondary Outcome Measures

  1. Vaccine interest [one year]

    To identify whether adults who are not vaccinated against HPV are interested in receiving the vaccine.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • between the ages of 18 and 35 and have a verified vaccine record that shows they were not vaccinated with the HPV vaccine or have not had a complete series of the vaccine before their visit.
Exclusion Criteria:
  • patients who have been vaccinated against HPV

  • patients under 18 and over 35

  • patients whose vaccine records cannot be verified

Contacts and Locations

Locations

Site City State Country Postal Code
1 Plan A Health, Inc Louise Mississippi United States 39097

Sponsors and Collaborators

  • Plan A Health, Inc
  • Merck Sharp & Dohme LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Plan A Health, Inc
ClinicalTrials.gov Identifier:
NCT05658198
Other Study ID Numbers:
  • 02
First Posted:
Dec 20, 2022
Last Update Posted:
Dec 20, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Plan A Health, Inc

Study Results

No Results Posted as of Dec 20, 2022